Candesartan cilexetil - Takeda
Alternative Names: Amias; Atacand; Blopress; Candesartan hexetil; Kenzen; Parapres; Ratacand; TCV-116; TiadylLatest Information Update: 05 Nov 2023
At a glance
- Originator Takeda
- Developer AstraZeneca; Takeda
- Class Antihypertensives; Benzimidazoles; Heart failure therapies; Tetrazoles
- Mechanism of Action Angiotensin type 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Heart failure; Hypertension
- Discontinued Coronary artery restenosis; Diabetic nephropathies; Diabetic retinopathy; Glomerulonephritis
Most Recent Events
- 04 Jan 2021 Candesartan cilexetil licensed to Cheplapharm Arzneimittel in Angola, Argentina, Aruba, Australia, Bahamas, Bahrain, Bermuda, Barbados, Benin, Botswana, Brazil, Brunei Darussalam, Burkina Faso, Cameroon, Canada, Cayman Islands, Chile, Colombia, Congo, Costa Rica, Curaçao, Côte D'Ivoire, Djibouti, Dominican Republic, Ecuador, Egypt, El Salvador, Gabon, Georgia, Ghana, Guatemala, Guinea, Haiti, Honduras, Iraq, Jamaica, Jordan, Kenya, Republic of Korea, Kuwait, Lebanon, Libya, Madagascar, Malaysia, Mali, Mauritania, Mauritius, Mexico, Namibia, New Zealand, Nicaragua, Niger, Nigeria, Oman, Palestine, Panama, Peru, Qatar, Russian Federation, Saudi Arabia, Senegal, Singapore, South Africa, Sri Lanka, Sudan, Togo, Trinidad and Tobago, Tunisia, Turkey, Ukraine, United Arab Emirates, Uruguay and Yemen for marketing
- 30 Oct 2020 AstraZeneca announces of its decision to divest commercial rights to candesartan cilexetil to Cheplapharm Arzneimittel GmbH
- 28 Mar 2020 Pooled efficacy results from the phase III CHARM-Alternative and CHARM-Preserved trials presented at the Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology Session (ACC-WCC-2020)